Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya. - Sang S; Datoo MS; Otieno E; Muiruri C; Bellamy D; Gathuri E; Ngoto O; Musembi J; Provstgaard-Morys S; Stockdale L; Aboagye J; Woods D; et al. (Wellcome open research, 2023)